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Abstract 
BACKGROUND: Mutations in the NPHS2 genes are the main aetiology of early-onset and familial steroid-
resistant nephrotic syndrome (SRNS). The pathogenic NPHS2 mutation together with the p.R229Q variant has 
been less described among Egyptian children.  
AIM: This study aims to determine the mutation of NPHS2 in children with NS and discover the role of p.R229Q 
variant in SRNS 
METHODS: The study included 53 children with NS, and 53 healthy volunteers matched in age and sex controls. 
The median age at disease onset was 7.3 years. Among NS cases, 31 cases had steroid-sensitive nephrotic 
syndrome (SSNS) and 22 children with steroid-resistant nephrotic syndrome (SRNS). Polymerase chain reaction 
amplification of the whole coding region of NPHS2 gene was carried out for its mutational analysis. Restriction 
digestion testing was carried out after PCR to determine the presence of R229Q polymorphism. Randomly 
selected samples were re-genotyped by two independent technicians for assessment of Quality control 
RESULTS: NS patients showed a significant higher frequency of heterozygous genotype GA (89.5%) compared 
to control group (10.5%) with increased risk of NS (OR, 12.04; 95% CI, 2.61 to55.38; p < 0.0001). Moreover, 
SRNS showed a significant higher frequency of GA genotype (68.2%) than the SSNS group (6.5%). The GA 
genotype was associated with increased risk of SRNS (OR, 31.1; 95% CI, 5.73 to 168.48; P < 0.001) and the A 
allele was associated with increased risk of SRNS (OR, 15.52; 95% CI, 3.325 to 72.422; P < .001). 
CONCLUSION: R229Q polymorphisms are associated with SRNS, and any child with SRNS should be searched 
for mutations in the NPHS2 gene. 
 
 
 
 
 
 
Introduction 
 
The most common primary glomerular 
disease in children is nephrotic syndrome (NS). 
Nephrotic syndrome in children is classified as 
having steroid-sensitive (SSNS) or steroid-resistant 
(SRNS) [1]. 
NPHS2 gene mutation has been reported in 
10–30% of children with sporadic SRNS children [2]. 
The frequency of SNP (p.R229Q) which is the most 
frequently reported polymorphism among SRNS is 5% 
in the European population as compared to healthy 
one [3]. Progressive damage of the glomerular 
filtration barrier occurs in these patients resulting in 
the development of end-stage renal disease (ESRD) 
[4]. An autosomal recessive form of SRNS with an 
early onset of the disease occurs due to mutations in 
the NPHS2 gene. One of the major glomerular 
diseases in Egyptian children is idiopathic NS and 
about 30% of these NS children is resistant to 
treatment by steroids [5].  
In contrary, in other parts of the world , 
resistance to steroid therapy is prevalent in10–20% of 
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cases of NS [6]. Therefore, the aim of this study is to 
analyze the mutation of NPHS2 gene in Egyptian 
children by applying next generation sequencing 
(NGS) and determine the role of SNPs in Egyptian 
children, concentrating our analyses on SRNS 
children carrying the p.R229Q variant.  
 
 
Subjects and Methods 
 
The current case control study was conducted 
on 53 patients with nephrotic syndrome (NS) and 53 
healthy volunteers with matched age and sex during 
the period from January 2017 to June 2018.The 
patients were referred from the Pediatric Nephrology 
Units, Al Zahra and Al – Hussein hospitals, Al-Azhar 
University, Cairo, Egypt. The clinical records of all the 
subjects were reviewed for age at onset, gender, 
family history, treatment modalities and response to 
therapy. 
All patients were diagnosed as nephrotic 
syndrome according to their clinical presentation and 
laboratory studies. The patient's group was 
categorized into 2 groups: 21 children with SRNS and 
32 children with SSNS. Steroid responsive NS 
(SSNS) was regarded as complete remission 
achieved with steroid therapy. Steroid-resistant NS 
(SRNS) was regarded as failure to achieve remission 
following 4-week prednisone 60 mg/m2 followed by 
three methylprednisolone pulses [7], [8]. 
The informed consent forms were given by 
caregiver of patients. 
The study protocol was approved by the 
medical Research Ethical Committee of AL-Azhar 
University. 
Genomic DNA was extracted from peripheral 
leukocytes of whole-blood samples using standard 
laboratory protocols. 
The 5 mL blood samples were drawn into 
tubes containing EDTA. Genomic DNA was extracted 
from peripheral leukocytes using standard techniques. 
NPHS2exon 5 was polymerase chain reaction (PCR)-
amplifiedusing the following primers: F 5'-
AGGATTTACCACAGGATTAAGTTGTGCA – 3' and R 
5'-TAGCTATGAGCTCCCAAAGGGATGG – 3'. Three 
microliters of unpurified PCR product were diluted to 
10 lL in recommended restriction buffer containing 5 U 
of ClaI and digested at 37°C overnight. The PCR 
products were visualized by electrophoresis in a 3% 
agarose gel with ethidiumbromide and stored in digital 
form. Quality control for these assays was assessed 
by randomly selecting 50 samples to be re-genotyped 
by two independent technicians. Each batch of 
restriction digestion contained a positive control 
(confirmed G allele) to avoid mistyping. 10% of the 
samples were randomly picked and re-genotyped to 
give consistent results. The products were resolved 
on 2% agarose gel and viewed in a gel documentation 
unit (Bio-Rad). Quality control for these assays was 
assessed by randomly selecting 30 samples to be 
regenotyped by two independent technicians. 
 
Statistical Analysis 
The SPSS version 21 was used in this 
research. Chi-square test (
2
) was used for 
comparison of frequencies between patients and 
controls and t test was used for comparing means. 
The association between case-control status and 
each polymorphism, measured by the odds ratio (OR) 
and its corresponding 95% confidence interval (CI). 
Hardy-Weinberg equilibrium was checked using 
2
 
test to compare the observed genotype frequencies 
with the expected frequencies among the case and 
control subjects. 
 
 
Results 
 
Table 1 shows distribution of genotypes of 
R229Q polymorphism in NS patients compared to 
control group. NS patients showed significant higher 
frequency of heterozygous GA genotype (89.5%) 
compared to control group (10.5%); (2 = 14.43; p < 
0.001), and increased risk of NS (OR, 12.04; 95% CI, 
2.61 to 55.38; p < 0.0001).  
Table 1: Genotypes distribution of R229Q polymorphism in NS 
cases and controls 
Genotype NS 
(n = 53) 
Controls 
(n = 53) 
Odds ratio (95% 
Confidence 
Interval) 
P value 
Genotype 
 
GG 
 
36 (41.4%) 
 
51 (58.6%) 
 
 
1 
 
GA 17(89.5%) 2 (10.5%) 12.04 (2.61-55.38) < 0.0001 
AA 0 0 -- -- 
2= 14.43; P < 0.001 
 
Table 2 shows comparison of the genotype's 
distribution of R229Q polymorphism between SRNS 
and SSNS patients. Significant increase of 
heterozygous genotype (GA) was observed in SRNS 
(68.2%) as compared to SSNS patients (6.5%) 2 = 
22.5; P < 0.001.  
Table 2: Genotypes and allele frequency distribution of R229Q 
polymorphism in children with SRNS and SSNS 
Genotype SRNS (n = 22 SSNS (n = 31) Odds ratio (95% 
Confidence Interval) 
P value 
GG 7 (31.8%) 29 (93.5%) 1  
GA 15 (68.2%) 2 (6.5%) 31.1 (5.73-168.48) < 0.0001 
AA 0 0   
x2= 22.51 p < 0.001 
Allele     
G 29 (32.9%) 60 (67%) 1  
A 15 (88.2%) 2 (11.8%) 15.52 (3.325-72.422) < 0.0001 
 
The GA genotype was associated with 
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increased risk of SRNS (OR, 31.1; 95% CI, 5.73 to 
168.48; P < 0.001) and the A allele was associated 
with increased risk of SRNS (OR, 15.52; 95% CI, 
3.325 to72.422; P < 0.001). 
Amplified PCR products in 6 healthy subjects 
with wild genotype (GG) were illustrated in Figure 
1(left). Moreover, PCR product of exon 5 of NPHS2 
gene for three patients and two healthy controls with 
wild genotype (GG) of R229Q and for one patient with 
the heterozygous genotype (GA) of R229Q was 
illustrated in Figure 1(right).  
  
Figure 1: Amplified PCR products in 6 healthy subjects (left); 
Agarose gel stained with ethidium bromide illustrating PCR product 
of exon 5 of NPHS2 gene before and after digestion with ClaI 
endonuclease enzyme for patients and healthy controls with wild 
genotype (GG) of R229Q and for one patient with the heterozygote 
genotype (GA) of R229Q (right) 
 
Figure 2(left) shows sequence chromatogram 
of exon 5 of NPHS2 gene, illustrating wild pattern GG. 
Figure 2(right) shows sequence chromatogram of 
exon 5 of NPHS2 gene and heterozygous pattern 
(p.Arg229 Gln) (c.686G ˃ A). Site of mutation is 
denoted by the arrow. 
  
Figure 2: Sequence chromatogram of exon 5 of NPHS2 gene 
showing wild pattern (p.Arg 229Gln) (c.686G ˃ A). Site is denoted 
by the arrow (left); Sequence chromatogram of exon 5 of NPHS2 
gene showing heterozygous pattern (p.Arg229 Gln) (c.686G ˃ A). 
Site of mutation is denoted by the arrow (right) 
 
 
Discussion 
 
The R229Q polymorphism (c.686G > A; 
rs61747728) is considered a non-neutral 
polymorphism and it has also been associated with 
glomerular disease. It is a podocin variant resulting in 
an amino acid substitution from arginine to glutamine 
in∼1 – 2% of European populations; the R229Q 
variant is being present and is associated with the 
development of microalbuminuria. The adult-onset 
FSGS is the result of compound heterozygosity of the 
R229Q variant with a pathogenic podocin mutation [9]. 
The role of NPHS2 mutations in adult onset disease 
have limited confirmation because of identification of 
few cases [10], [11], [12]. Few studies reported the 
effect of p.R229Q and p.P20L in causing disease in 
European, North American Caucasian and South 
American populations [13], [14]. A non-conservative 
substitution was caused by p.P20L in a previous study 
[15]. In the Czech population, the highest frequency of 
p.R229Q has been reported (12%) [16]. An increased 
(2 – 3 folds) risk of micro albuminuria with progression 
gradually to ESRD at the age of thirty and forty years 
is caused by p.R229Q, with tendency to have later-
onset disease (i.e. typically FSGS) [17].The single 
heterozygous mutation (p.R229Q) could not by itself 
be considered as a causative mutation because a 
previous study predicted 2 NPHS2 gene SNPs, a 
heterozygous 1082T > C and a homozygous 954T > 
CA [4]. A low prevalence of the two genes in 
Japanese and Chinese NS patients was reported in 
several studies [18], [19]. There are a number of other 
genes make a significant contribution to the spectrum 
of disease-causing mutations beside the NPHS1 and 
NPHS2 genes. In familial autosomal-recessive 
steroid-resistant nephrotic syndrome NPHS2 
mutations was detected for the first time by [20]. Also, 
in sporadic cases of steroid-resistant nephrotic 
syndrome [2], [15], [21] and late-onset focal 
segmental glomerulosclerosis (FSGS) [12], NPHS2 
mutations were identified thereafter. Individuals with 
the same genotype revealed a wide range of 
phenotypic variability [19]. In a previous study the 
mutation detection rate in familial autosomal-recessive 
and sporadic steroid-resistant nephrotic syndrome 
was 43% and 10.5% respectively [22]. The NPHS2 
mutations were present in patients of Italian, French, 
German, and Israeli-Arab origin, but it is not present in 
children of Israeli-Jewish and Japanese origin [2], 
[15], [21]. 
In conclusion, NPHS2 mutations were 
observed in the studied Egyptian children with 
nephrotic syndrome and significant higher frequency 
was detected in SRNS cases. Therefore, every child 
with SRNS should be searched for mutations in 
NPHS2 gene by target-oriented next generation 
sequencing analysis. Moreover, mutational analysis of 
NPHS2 genes should be included in the diagnosis of 
NS among Egyptian patients. 
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